Jpmorgan Chase & CO Viridian Therapeutics, Inc.\De Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Jpmorgan Chase & CO holds 125,710 shares of VRDN stock, worth $2.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

125,710

Previous 49,023 156.43%

Holding current value

$2.8 Million

Previous $858,000 90.56%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$11.6 - $17.26 $889,569 - $1.32 Million	76,687 Added 156.43%	125,710 $1.64 Million
Q1 2024 May 10, 2024	SELL	$17.09 - $23.82 $135,267 - $188,535	-7,915 Reduced 13.9%	49,023 $858,000
Q4 2023 Feb 12, 2024	BUY	$11.12 - $22.5 $66,897 - $135,360	6,016 Added 11.81%	56,938 $1.24 Million
Q3 2023 Nov 14, 2023	SELL	$15.16 - $24.7 $137,198 - $223,535	-9,050 Reduced 15.09%	50,922 $781,000
Q2 2023 Aug 11, 2023	BUY	$22.57 - $29.67 $239,129 - $314,353	10,595 Added 21.46%	59,972 $1.43 Million
Q1 2023 May 18, 2023	BUY	$25.04 - $37.6 $1.23 Million - $1.84 Million	48,998 Added 12928.23%	49,377 $1.26 Million
Q1 2023 May 11, 2023	SELL	$25.04 - $37.6 $4.31 Million - $6.47 Million	-171,980 Reduced 99.78%	379 $9,000
Q4 2022 Feb 13, 2023	BUY	$18.78 - $29.74 $1.94 Million - $3.07 Million	103,101 Added 148.87%	172,359 $5.03 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $544,833 - $1.3 Million	50,919 Added 277.65%	69,258 $1.42 Million
Q2 2022 Aug 11, 2022	SELL	$9.55 - $19.0 $3,122 - $6,213	-327 Reduced 1.75%	18,339 $213,000
Q1 2022 May 11, 2022	BUY	$16.79 - $20.88 $94,578 - $117,617	5,633 Added 43.22%	18,666 $345,000
Q4 2021 Feb 10, 2022	BUY	$15.65 - $21.5 $203,966 - $280,209	13,033 New	13,033 $258,000

Others Institutions Holding VRDN

# of Institutions

152

Shares Held

61.9M

Call Options Held

133K

Put Options Held

207K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $889M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Viridian Therapeutics, Inc.\De Transaction History